LIFE aTyr Pharma Inc.

2.82
-0.06  -2%
Previous Close 2.88
Open 2.91
Price To Book 1.24
Market Cap 26,374,044
Shares 9,352,498
Volume 53,884
Short Ratio
Av. Daily Volume 204,338
Stock charts supplied by TradingView

NewsSee all news

  1. aTyr Pharma Announces Fourth Quarter and Full Year 2019 Results and Provides Corporate Update

    Company to host conference call and webcast today at 5:00 p.m. EDT / 2:00 p.m. PDT SAN DIEGO, March 26, 2020 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (NASDAQ:LIFE), a biotherapeutics company engaged in the discovery and

  2. aTyr Pharma and its Hong Kong Subsidiary, Pangu BioPharma, Announce Government Grant to Fund Bispecific Antibody Development Platform

    Grant awarded by the Hong Kong Government's Innovation and Technology Commission under the Partnership Research Program Two-year project will initially focus on development of new bi-specific antibodies

  3. aTyr Pharma to Announce Fourth Quarter and Full Year End 2019 Financial Results on March 26th

    SAN DIEGO, March 19, 2020 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (NASDAQ:LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological pathways, today

  4. Leading Cancer Researcher Dr. Arthur M. Mercurio Joins aTyr as Scientific Advisor

    SAN DIEGO, March 17, 2020 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (NASDAQ:LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological pathways, today

  5. aTyr Pharma Announces Exercise and Closing of Over-Allotment Option in Public Offering

    SAN DIEGO, March 10, 2020 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (NASDAQ:LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological pathways, today

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 1/2 final data presented October 5, 2017 at the International Annual Congress of the World Muscle Society (WMS).
Resolaris
Early onset facioscapulohumeral muscular dystrophy (FSHD)
Phase 1b/2 data released December 13, 2016 with further update at EASL April 2017.
Resolaris
Limb girdle muscular dystrophy (LGMD) 2B / Adult patients with facioscapulohumeral muscular dystrophy (FSHD)
Phase 1/2 interim data noted treatment was generally safe and well tolerated - December 12, 2019. Final data due mid-2020.
ATYR1923
Pulmonary sarcoidosis

Latest News

  1. aTyr Pharma Announces Fourth Quarter and Full Year 2019 Results and Provides Corporate Update

    Company to host conference call and webcast today at 5:00 p.m. EDT / 2:00 p.m. PDT SAN DIEGO, March 26, 2020 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (NASDAQ:LIFE), a biotherapeutics company engaged in the discovery and

  2. aTyr Pharma and its Hong Kong Subsidiary, Pangu BioPharma, Announce Government Grant to Fund Bispecific Antibody Development Platform

    Grant awarded by the Hong Kong Government's Innovation and Technology Commission under the Partnership Research Program Two-year project will initially focus on development of new bi-specific antibodies

  3. aTyr Pharma to Announce Fourth Quarter and Full Year End 2019 Financial Results on March 26th

    SAN DIEGO, March 19, 2020 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (NASDAQ:LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological pathways, today

  4. Leading Cancer Researcher Dr. Arthur M. Mercurio Joins aTyr as Scientific Advisor

    SAN DIEGO, March 17, 2020 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (NASDAQ:LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological pathways, today

  5. aTyr Pharma Announces Exercise and Closing of Over-Allotment Option in Public Offering

    SAN DIEGO, March 10, 2020 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (NASDAQ:LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological pathways, today

  6. aTyr Pharma Announces Poster Presentation at the American Association for Cancer Research (AACR) Annual Meeting

    SAN DIEGO, March 03, 2020 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (NASDAQ:LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological pathways, today

  7. aTyr Pharma Announces Publication in the Journal Cellular and Molecular Immunology

    Paper highlights the essential role that histidyl tRNA synthetase (HARS) plays in immune responses in a broad range of inflammatory disease states Lead therapeutic candidate, ATYR1923, being evaluated in a Phase 1b/2a

  8. aTyr Pharma Announces Pricing of $18 million Underwritten Public Offering

    SAN DIEGO, Feb. 06, 2020 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (NASDAQ:LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological pathways, today

  9. aTyr Pharma Announces Collaboration with Kyorin Pharmaceutical Co., Ltd. for the Development and Commercialization of ATYR1923 in Japan

    aTyr eligible to receive up to $175 million in total payments, including $8 million upfront, plus tiered sales royalties Kyorin to fund all ATYR1923 development and commercialization activities in Japan SAN DIEGO, Jan.

  10. aTyr Pharma Announces Third Quarter 2019 Results and Provides Corporate Update

    Interim safety results from Phase 1b/2a proof-of-concept trial of ATYR1923 in pulmonary sarcoidosis patients due in December 2019 Company to host conference call and webcast today, November 14, at 5:00pm EDT SAN DIEGO,

  11. aTyr Pharma to Present at the Stifel Healthcare Conference 2019

    SAN DIEGO, Nov. 13, 2019 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (NASDAQ:LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological pathways, today

  12. aTyr Pharma to Announce Third Quarter Results on November 14th

    SAN DIEGO, Nov. 07, 2019 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (NASDAQ:LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological pathways, today

  13. aTyr Pharma Announces Research Collaboration with Boston Children's Hospital

    SAN DIEGO, Oct. 22, 2019 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (NASDAQ:LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological pathways, today

  14. aTyr Pharma to Participate in September Conferences

    SAN DIEGO, Sept. 18, 2019 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (NASDAQ:LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological pathways, today

  15. aTyr Pharma to Present at the H.C. Wainwright 21st Annual Global Investment Conference

    SAN DIEGO, Sept. 04, 2019 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (NASDAQ:LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological pathways, today